Cross-study analyses of the ropeginterferon alfa-2b effect on phlebotomy in low- and high-risk patients with polycythemia vera.
Key claim: Ropeginterferon alfa-2b achieves durable hematocrit control and phlebotomy independence across low- and high-risk PV, with the accelerated HIDAT regimen yielding faster phlebotomy-free responses and deeper JAK2V617F allele-burden reduction than slow titration.
Abstract
Therapeutic phlebotomy maintains hematocrit (Hct) <45% in patients with polycythemia vera (PV) and reduces thrombotic risks. However, frequent phlebotomy can induce iron deficiency. Ropeginterferon alfa-2b (ropeg) is a new-generation interferon therapy that induces durable complete hematologic and molecular responses through reduction of the()-mutated clone. Two dosing regimens have been investigated: the FDA-approved slow-titration regimen and a higher initial dose and accelerated titration (HIDAT) regimen. A cross-analysis of three prospective trials showed that ropeg achieved sustained Hct control and reduction of phlebotomy dependence in PV patients, including high-risk and hydroxyurea-resistant/intolerant patients. In exploratory cross-study comparisons, the HIDAT regimen was associated with more rapid phlebotomy-free Hct response rates, lower mean annualized phlebotomy frequency, higher overall hematologic response rates and deeperV617F allele burden reduction than slow titration. Both regimens were safe and well tolerated. Ropeg treatment provides durable Hct control and phlebotomy-independence in a broad PV population, including high-risk patients.
Why this matters
Ropeginterferon alfa-2b is emerging as a disease-modifying frontline option across the PV risk spectrum, and this cross-study synthesis directly addresses the practical question of dosing strategy — showing that the accelerated HIDAT regimen delivers earlier phlebotomy independence and deeper JAK2V617F molecular response than conventional slow titration. For PV natural history, this reinforces that both low- and high-risk (and HU-resistant) patients benefit, sharpening the case for early ropeg initiation and informing the frontline sequencing debate alongside MITHRIDATE and givinostat comparators.